• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Pharmaceutical Product Development

Pharmaceutical Product Development

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

    Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting

  2. Services Super Sector: Major Themes

    Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.